Skip to main content
Journal cover image

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.

Publication ,  Journal Article
Reardon, DA; Zalutsky, MR; Akabani, G; Coleman, RE; Friedman, AH; Herndon, JE; McLendon, RE; Pegram, CN; Quinn, JA; Rich, JN; Vredenburgh, JJ ...
Published in: Neuro Oncol
April 2008

The purpose of this study was to determine the feasibility and assess the efficacy and toxicity, among newly diagnosed malignant glioma patients, of administering (131)I-labeled murine antitenascin monoclonal antibody 81C6 ((131)I-81C6) into a surgically created resection cavity (SCRC) to achieve a patient-specific, 44-Gy boost to the 2-cm SCRC margin. A radioactivity dose of (131)I-81C6 calculated to achieve a 44-Gy boost to the SCRC was administered, followed by conventional external beam radiotherapy (XRT) and chemotherapy. Twenty-one patients were enrolled in the study: 16 with glioblastoma multiforme (GBM) and 5 with anaplastic astrocytoma. Twenty patients received the targeted 44-Gy boost (+/-10%) to the SCRC. Attributable toxicity was mild and limited to reversible grade 3 neutropenia or thrombocytopenia (n = 3; 14%), CNS wound infections (n = 3; 14%), and headache (n = 2; 10%). With a median follow-up of 151 weeks, median overall survival times for all patients and those with GBM are 96.6 and 90.6 weeks, respectively; 87% of GBM patients are alive at 1 year. It is feasible to consistently achieve a 44-Gy boost dose to the SCRC margin with patient-specific dosing of (131)I-81C6. Our study regimen ((131)I-81C6 + XRT + temozolomide) was well tolerated and had encouraging survival. To determine if selection of good-prognosis patients affects outcome associated with this approach, the U.S. Food and Drug Administration has approved a trial randomizing newly diagnosed GBM patients to either our study regimen or standard XRT plus temozolomide.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Neuro Oncol

DOI

ISSN

1522-8517

Publication Date

April 2008

Volume

10

Issue

2

Start / End Page

182 / 189

Location

England

Related Subject Headings

  • Tenascin
  • Radioimmunotherapy
  • Pilot Projects
  • Oncology & Carcinogenesis
  • Middle Aged
  • Mice
  • Male
  • Kaplan-Meier Estimate
  • Iodine Radioisotopes
  • Injections, Intralesional
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reardon, D. A., Zalutsky, M. R., Akabani, G., Coleman, R. E., Friedman, A. H., Herndon, J. E., … Bigner, D. D. (2008). A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol, 10(2), 182–189. https://doi.org/10.1215/15228517-2007-053
Reardon, David A., Michael R. Zalutsky, Gamal Akabani, R Edward Coleman, Allan H. Friedman, James E. Herndon, Roger E. McLendon, et al. “A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.Neuro Oncol 10, no. 2 (April 2008): 182–89. https://doi.org/10.1215/15228517-2007-053.
Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE, et al. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol. 2008 Apr;10(2):182–9.
Reardon, David A., et al. “A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.Neuro Oncol, vol. 10, no. 2, Apr. 2008, pp. 182–89. Pubmed, doi:10.1215/15228517-2007-053.
Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, Dowell JM, Wong TZ, Zhao X-G, Friedman HS, Bigner DD. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol. 2008 Apr;10(2):182–189.
Journal cover image

Published In

Neuro Oncol

DOI

ISSN

1522-8517

Publication Date

April 2008

Volume

10

Issue

2

Start / End Page

182 / 189

Location

England

Related Subject Headings

  • Tenascin
  • Radioimmunotherapy
  • Pilot Projects
  • Oncology & Carcinogenesis
  • Middle Aged
  • Mice
  • Male
  • Kaplan-Meier Estimate
  • Iodine Radioisotopes
  • Injections, Intralesional